You are here

2021 Virtual Poster Session

Vertical Tabs

Vertical Tabs

Register for Virtual Poster Session

Virtual Poster Session

If you have trouble viewing this page, click here

29 Confirmed Posters

List of Confirmed Posters

2021 Poster Session: A Virtual Experience
Date of CE Release:  July 15, 2021
Date of CE Expiration:  December 31, 2021
Location: Online


3 Change In Reported Resilience After Repetitive Transcranial Magnetic Stimulation (rTMS) for Major Depressive Disorder at a Suburban Tertiary Clinic Amelia Hess
4 Ketamine Therapy Combined With Repetitive Transcranial Magnetic Stimulation (rTMS) FOR Major Depressive Disorder at a Suburban Tertiary Clinic Amelia Hess
7 Deep-TMS for Negative Symptoms of Schizophrenia Aron Tendler, MD
8 Deep-TMS for Chronic Non-Cancer Pain Syndromes including CRPS Aron Tendler, MD
10 A Retrospective Review of Patients with Post-Traumatic Stress Syndrome (PTSD) treated by Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS®) Milan Makale
11 Repeat Transcranial Magnetic Stimulation (TMS) Treatment Cycles In An Elderly Patient With Recurrent Resistant Depression And A History Of Seizures: A Call for Maintenance Therapy Debra Stultz, MD
12 Transcranial Magnetic Stimulation (TMS) Improvement in Depression, Insomnia, and Fatigue Associated with Multiple Sclerosis (MS) Debra Stultz, MD
13 iTBS Combined with Cognitive Behavioral Therapy for Treatment Resistant Depression (TRD) Jose Cruz, MD
14 Repetitive Transcranial Magnetic Stimulation in the Treatment of Major Depression During Pregnancy: A Case Series Martha Koo, M.D.
15 Transcranial Magnetic Stimulation Outcomes by Age: A Retrospective Chart Review in a Naturalistic Clinic Setting Martha Koo, M.D.
16 Transcranial Magnetic Stimulation for the Treatment of Major Depression: A Retrospective Outcome Study Comparing the Effectiveness of rTMS Therapy Across Age and Gender Randy Pardell, MD
17 Mechanical Affective Touch Therapy (MATT) for Anxiety Disorders: Clinical Outcomes and EEG Biomarkers in an Open-Label Clinical Trial Eric Tirrell
18 Ecological Momentary Assessment (EMA)-Guided TMS Maintenance Therapy for Prevention of Depression Relapse: A Feasibility Pilot Study Eric Tirrell
19 Deep TMS for the Treatment of Comorbid Anxiety Yiftach Roth, PhD
20 A Comparison of final YBOCS in patients receiving either rTMS to the Right DLPFC + SMA or FP1 for the treatment of OCD Harpreet Singh, MD
21 Efficacy of Unilateral Vs. Bilateral rTMS Treatment on Suicidal Ideation In Patients With Depression and Comorbid Anxiety Jonathan Downar, MD, PhD, FRCPC
22 Evaluation of 1 HZ/20 HZ Bilateral Rtms Effects on Cognitive Performance In Patients With Major Depressive Disorder Using Thinc-It® Jonathan Downar, MD, PhD, FRCPC
24 Network-Targeted Prefrontal Transcranial Magnetic Stimulation (TMS) in Neuropsychiatric and Neurodegenerative Disorders Joy L. Taylor, PhD
25 The Outcomes & Comparative Efficacy of Left VS Right Sided TMS for Females with a Co-Diagnosis Of MDD & GAD Karan Narwal, MD
28 Does baseline OCD and Depression scores, age and gender predict remission in patients receiving rTMS for the treatment of OCD? Lorelei-Jane Wyman
32 Clinical Effectiveness of 1 HZ/20 HZ Bilateral rTMS Treatment in Adolescents with Major Depressive Disorder Paul Croarkin, MD
35 Analysis of Multi-Center MDD Trials Indicates Direct, Polysymptomatic Effect of rTMS on Depression and Anxiety with H1-coil and Delayed, Indirect Effect on Anxiety with Figure-8 Coil Samuel Zibman
37 Systematic Review of Preservation TMS that includes Continuation, Maintenance, Relapse-prevention, and Rescue TMS Saydra Wilson, MD
38 Comparison of Left Unilateral TMS Treatment vs. Sequential Bilateral Treatment in a Large Registry Cohort Scott T. Aaronson, MD
39 Effects of D-Cycloserine on the Primary Motor Cortex Excitability in Healthy Human Subjects: A Paired-Pulse TMS Protocol Shiwen Yuan
41 Ramsay Hunt Syndrome Treated with TMS - A Case Report Todd Hutton, MD
44 Deep rTMS of the Insula Disrupts Cigarette Self-Administration and Modulates Insula-Centric Brain Function in Smokers with Schizophrenia Lucian Manu, MD
45 To Continue or Not – A Case Report on TMS Maintenance Irakli Mania, MD
46 Transcranial Magnetic Stimulation in US Military Veterans – A Naturalistic Study in the Veterans Health Administration Andrew Kozel, MD, MSCR

Acknowledgment of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgment of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must review each poster chosen and take up to 15 minutes to absorb the information and complete an evaluation form to receive a certificate of completion.

Complete all posters you wish to view before completing the evaluation.

If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.  


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 7.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Objectives - After Attending This Program You Should Be Able To

  1. Identify evidence for various TMS treatment approaches compared to standard TMS approach
  2. Discuss the effectiveness of TMS in various populations and settings
  3. Discuss predictive biomarkers and/or clinical markers of response to repetitive transcranial magnetic stimulation (rTMS) treatment

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed on the website. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

First Name

Last Name

Commercial Interest: Relationship



Neuronetics:Research Grant Site Principal Investigator,Janssen:Consultant,Sage Therapeutics:Consultant,Compass Pathways:Research Grant Site Principal Investigator,Genomind:Scientific/Medical Advisory Board Member,LivaNova:Consultant,Neurolief:Consultant,Neuronetics:Consultant,Compass Pathways:Research Grant Overall Principal Investigator



Neuronetics, Inc:Research Grant Site Principal Investigator,Pfizer, Inc:Research Grant Overall Principal Investigator,Assurerx Health:Other,Procter & Gamble Company:Consultant,Sunovian :Scientific/Medical Advisory Board Member,NeoSync:Research Grant Site Principal Investigator,MagVenture: Equipment Support ,Myriad Neuroscience:Consultant,Engrail Therapeutics:Scientific/Medical Advisory Board Member,Neuronetics:Equipment Support



Smart Health & Wellness Centers:Stock Shareholder,Salience TMS Neuro Solutions:Scientific/Medical Advisory Board Member,Smart Health & Wellness Centers:Scientific/Medical Advisory Board Member



Neuronetics:Other Financial or Material Support/consultant,Cyberonics/Livanova:Other Financial or Material Support/Research support,Janssen:Consultant



Neuronetics:Consultant,Southern California TMS Center:Stock Shareholder



Salience TMS Neuro Solutions:Stock Shareholder



Commercial interest:Own BrainsWay TMS machine



Research Funding:Research Grant Site Principal Investigator



Smart TMS:Medical Director of Smart TMS



Smart TMS:Medical Director of Smart TMS



Neuronetics :Co-marketing



Neuronetics :Co-marketing






BrainsWay Ltd.:Stock Shareholder



Jazz Pharmaceticuls:Speakers Bureau,Harmony Biosciences:Speakers Bureau



Brainsway:Consultant,Brainsway:Stock Shareholder